文献速递乳腺癌放疗放疗物理与技术

氯沙坦联合放疗提高HER2/neu阳性乳腺癌模型肿瘤控制并抑制肺转移

Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model.
PubMed 文献 · Radiat Oncol · 2021-03-04

在HER2/neu阳性小鼠乳腺癌原位模型中,氯沙坦(40 mg/kg体重,每日灌胃7天)联合20 Gy单次或5×4 Gy分次局部照射,较单纯放疗进一步延长肿瘤生长延迟5-8天(P<0.01)、减少肺转移(P<0.025)并提高生存(P=0.0303)。氯沙坦显著增加肿瘤血管密度(P=0.0314)并减少缺氧面积(P=0.0002)。

要点

  • 氯沙坦联合单次或分次放疗较单纯放疗进一步延长肿瘤生长延迟5-8天(P<0.01)。
  • 联合治疗减少自发性肺转移(P<0.025)并提高动物生存(P=0.0303)。
  • 氯沙坦增加肿瘤血管密度(P=0.0314)并减少缺氧面积(P=0.0002)。

核心结论

  • 氯沙坦联合局部照射显著增强HER2/neu阳性乳腺癌模型的肿瘤控制,部分通过增加肿瘤灌注减少缺氧实现。
  • 该联合策略是改善HER2阳性乳腺癌局部控制和抑制转移的潜在新治疗方向。

研究设计与样本

  • 采用HER2/neu阳性小鼠乳腺癌细胞系MCa-M3C在同系雌性FVB/N小鼠乳腺脂肪垫建立原位同种移植瘤模型。
  • 从原位种植后第3天起给予7天氯沙坦(40 mg/kg体重,每日灌胃),第10天(肿瘤约100 mm3)给予20 Gy单次局部照射或第10-14天给予20 Gy分次照射(5×4 Gy每日)。
  • 分析指标包括肿瘤生长延迟、自发性肺转移、动物生存、肿瘤血管密度和肿瘤缺氧。

主要发现

  • 单次照射、分次照射、氯沙坦+单次照射、氯沙坦+分次照射均较对照显著增加MCa-M3C肿瘤生长延迟8-16天。
  • 氯沙坦+单次照射和氯沙坦+分次照射较单纯放疗进一步增加肿瘤生长延迟5-8天(P<0.01)。
  • 氯沙坦+放疗较对照减少肺转移(P<0.025)并提高动物生存(P=0.0303)。
  • 氯沙坦显著增加肿瘤血管密度(P=0.0314)并减少哌莫硝唑阳性缺氧面积(P=0.0002)。

关键数值与推荐

  • 氯沙坦剂量为40 mg/kg体重,每日灌胃,持续7天。
  • 放疗剂量为20 Gy单次局部照射或20 Gy分次照射(5×4 Gy每日)。
  • 联合治疗较单纯放疗进一步延长肿瘤生长延迟5-8天(P<0.01)。
  • 联合治疗较对照减少肺转移(P<0.025)并提高生存(P=0.0303)。

临床怎么用

  • 在HER2/neu阳性乳腺癌放疗中,可考虑联合氯沙坦以增强局部控制并抑制肺转移。
  • 氯沙坦可能通过改善肿瘤灌注和减少缺氧来增敏放疗。

局限性

  • 证据来自临床前小鼠原位乳腺癌模型,尚未在患者中验证。
  • 氯沙坦给药时机和剂量方案与临床实践可能存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with metastatic HER2/neu-positive (HER2/neu +) breast cancer (BC) often experience treatment resistance, disease recurrences and metastases. Thus, new approaches for improving the treatment of HER2/neu + BC to prevent metastatic dissemination are urgently needed. Our previous studies have shown that losartan, an angiotensin receptor blocker, increases tumor perfusion and decreases hypoxia in a number of tumor models. Hypoxia reduces the efficacy of radiation and increases metastases. We therefore hypothesized that by modifying tumor stroma and increasing oxygenation, losartan will improve the outcome of radiotherapy and inhibit disease progression in a highly metastatic HER2/neu + murine BC model. METHODS: We established a metastatic HER2/neu + murine BC line (MCa-M3C) and used it to generate mammary fat pad isografts in syngeneic female FVB/N mice. Starting on day 3 after orthotopic tumor implantation, we administered a 7-day losartan treatment (40 mg/kg BW, gavage daily); or a 7-day losartan treatment followed by 20 Gy single dose local irradiation (S-IR) on day 10 (tumor size ~ 100 mm3), or 20 Gy local fractionated (5 × 4 Gy daily) irradiation (F-IR) on days 10-14. We analyzed tumor-growth delay (TGD), development of spontaneous lung metastases, animal survival, tumor vascular density, and tumor hypoxia. RESULTS: Treatments with S-IR, F-IR, Losartan + S-IR, or Losartan + F-IR resulted in a significantly increased TGD (8-16 days) in MCa-M3C tumors versus controls. However, the combination of Losartan + S-IR and Losartan + F-IR further enhanced tumor response to radiation alone by increasing TGD an additional 5 to 8 days for both single and fractionated dose irradiation (P < 0.01), decreasing lung metastasis (Losartan + IR vs. Control, P < 0.025), and increasing animal survival (Losartan + IR vs. Control, P = 0.0303). In addition, losartan treatment significantly increased tumor vascularity (P = 0.0314) and decreased pimonidazole positive (hypoxic) area (P = 0.0002). CONCLUSIONS: Combining losartan with local irradiation significantly enhanced tumor response, at least in part via reduced tumor hypoxia presumably due to increased tumor perfusion. Our findings suggest that combining losartan with radiotherapy is a potential new treatment strategy for local control and inhibiting metastasis in HER2 + BC.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Li W, Li S, Chen IX, et al. Combining losartan with radiotherapy increases tumor control and inhibits lung metastases from a HER2/neu-positive orthotopic breast cancer model. Radiat Oncol. 2021. PMID: 33663521. doi:10.1186/s13014-021-01775-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。